# Dyne Therapeutics

> Dyne Therapeutics develops targeted medicines for genetic neuromuscular diseases. Its FORCE platform couples a transferrin-receptor-binding antibody fragment to a therapeutic payload to improve delivery to muscle and potentially the central nervous system. Its lead DMD candidate is under FDA review, while DM1 and FSHD programs remain in clinical development.

- **Founded:** 2017
- **Headquarters:** Waltham, United States
- **Founders:** Romesh Subramanian (Co-founder; former CEO and Chief Scientific Officer), Jason Rhodes (Founding President and CEO; board chairman)
- **Products:** FORCE platform, Zeleciment rostudirsen (z-rostudirsen; DYNE-251), Zeleciment basivarsen (z-basivarsen; DYNE-101), DYNE-302, Additional DMD and Pompe programs
- **Notable:** DELIVER registrational expansion cohort met its primary dystrophin endpoint in December 2025., FDA accepted z-rostudirsen’s BLA with Priority Review in July 2026., Completed enrollment of 71 participants in the ACHIEVE registrational expansion cohort in June 2026.

## Products & services

- **FORCE platform** — Proprietary Fab-linker-payload system targeting transferrin receptor 1 for delivery to muscle and potentially the CNS; a development platform, not a marketed medicine.
- **Zeleciment rostudirsen (z-rostudirsen; DYNE-251)** — Investigational Fab-PMO exon 51-skipping therapy for genetically eligible DMD patients. FDA Priority Review underway; target action date January 21, 2027. Phase 3 FORZETTO began in May 2026.
- **Zeleciment basivarsen (z-basivarsen; DYNE-101)** — Investigational Fab-ASO therapy designed to reduce toxic nuclear DMPK RNA in DM1; evaluated in ACHIEVE and Phase 3 HARMONIA.
- **DYNE-302** — Investigational Fab-siRNA targeting DUX4 for FSHD; FDA cleared its IND for a Phase 1 trial in July 2026.
- **Additional DMD and Pompe programs** — Preclinical DYNE-253, DYNE-245, DYNE-244 and DYNE-255 target exon skipping for exons 53, 45, 44 and 55; DYNE-401 targets Pompe disease.

## Achievements

- DELIVER registrational expansion cohort met its primary dystrophin endpoint in December 2025.
- FDA accepted z-rostudirsen’s BLA with Priority Review in July 2026.
- Completed enrollment of 71 participants in the ACHIEVE registrational expansion cohort in June 2026.
- Initiated confirmatory Phase 3 programs FORZETTO and HARMONIA in 2026.
- Received FDA IND clearance for DYNE-302 in July 2026.

## Latest updates

- **2026-09** — Reported additional one-year ACHIEVE data from a pooled mixed-dose group of 25-26 participants; confirmatory studies remain necessary.
- **2026-07** — FDA accepted z-rostudirsen BLA; target action date January 21, 2027. Approval is pending.
- **2026-07** — FDA cleared DYNE-302 IND for a Phase 1 FSHD study.
- **2026-07** — Closed approximately $431.4 million gross public offering. Reported June 30 cash, equivalents and marketable securities of $898.5 million; projected runway into Q2 2028 including July offering proceeds.

## Links

- Website: https://www.dyne-tx.com/
- LinkedIn: https://www.linkedin.com/company/dynetx
- Twitter/X: https://twitter.com/Dyne_tx
- Facebook: https://www.facebook.com/DyneTherapeutic/

---

Profile page: https://yespress.io/dyne-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-10-24